论文部分内容阅读
目的对琥珀酸美托洛尔缓释片在心律失常患者中的应用及对炎症因子的影响进行探究。方法 63例心律失常患者作为研究对象,并按照随机分配的原则将其分为实验组(32例)与对照组(31例)。实验组给予稳心颗粒联合琥珀酸美托洛尔缓释片进行治疗,对照组给予稳心颗粒进行治疗,对比并观察两组的临床效果。结果对照组治疗后的总有效率为74.19%,显著低于实验组的96.88%,差异有统计学意义(P<0.05)。治疗前,两组的C反应蛋白(CRP)、白细胞介素(IL)-8水平比较,差异均无统计学意义(P>0.05);治疗后,对照组的CRP为(4.87±1.70)mmol/L、IL-8水平为(101.45±12.49)mg/L,均高于实验组的(3.01±1.18)mmol/L、(86.15±12.57)mg/L,差异有统计学意义(P<0.05)。结论给予心律失常患者应用琥珀酸美托洛尔缓释片进行治疗,可有效改善患者的症状,提高临床预后,有临床推广与应用的价值。
Objective To investigate the application of metoprolol succinate sustained release tablets in patients with arrhythmia and its influence on inflammatory factors. Methods Sixty - three patients with arrhythmia were divided into experimental group (32 cases) and control group (31 cases) according to the principle of random distribution. The experimental group was given Wenxin granules combined with metoprolol succinate sustained-release tablets for treatment, while the control group was given Wenxin granules for treatment. The clinical effects of the two groups were compared and observed. Results The total effective rate of the control group after treatment was 74.19%, which was significantly lower than that of the experimental group (96.88%), the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in C-reactive protein (CRP) and interleukin (IL) -8 between the two groups (P> 0.05). After treatment, the CRP in the control group was (4.87 ± 1.70) mmol / L and IL-8 levels were (101.45 ± 12.49) mg / L, which were significantly higher than those in the experimental group (3.01 ± 1.18 mmol / L, 86.15 ± 12.57 mg / ). Conclusions The application of metoprolol succinate sustained-release tablets to patients with arrhythmia can effectively improve the symptoms of patients and improve the clinical prognosis, and has the value of clinical popularization and application.